[Use of Rokitamycin dry syrup in cases of upper deep cervical lymphadenitis and otitis media with exudatives].
Dry syrup of Rokitamycin (RKM.DS), a new macrolide antibiotic with 16-membered ring developed by Toyo Jozo Co., Ltd., was used on cases of upper deep cervical lymphadenitis (UDCL) and of otitis media with exudatives (OME) likely caused by chlamydia infections, and its clinical effects were investigated. 1) In four cases of UDCL (C. psittaci infections), daily doses of 20.0-28.6 mg/kg were administered for 10-42 consecutive days and good efficacies were observed with two cases of excellent results and two cases of good results. 2) In one case of OME (C. trachomatis infection) a daily dose of 30.0 mg/kg was administered for 15 consecutive days and good effectiveness was observed. 3) No side effect was observed in any of the cases. From the above results, it became clear that RKM.DS could effectively used as a therapeutic agent for UDCL and OME in children.
Mukai
S
S
Mukai
C
C
Asaoka
K
K
Murakami
S
S
Suzuki
I
I
D002648:Child; D002675:Child, Preschool; D002690:Chlamydia Infections; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D002691:Chlamydophila psittaci / Q000302:isolation & purification; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D008199:Lymphadenitis / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D015644:Miocamycin / Q000031:analogs & derivatives*; D009333:Neck; D010034:Otitis Media with Effusion / Q000188:drug therapy* / Q000382:microbiology; D009956:Psittacosis / Q000188:drug therapy
D007933:Leucomycins; D015644:Miocamycin; C033383:rokitamycin